Neurogene (NGNE) Stock Price
Neurogene Price
For Neurogene, the net margin of -8,123.7% is down versus -126.3% a few years ago. The consensus 12-month price target for Neurogene is 70.00 USD, about 170.6% above where the stock trades today. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus.
Neurogene stock price
Neurogene business model & stock analysis
Frequently asked questions about Neurogene
Analysts currently set an average price target of 72.00 USD for the Neurogene stock (median: 70.00 USD), implying +178.3 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Neurogene stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neurogene to generate revenue of 462,500.00 USD and earnings per share of -5.57 USD.
Converted at the current exchange rate, the Neurogene share trades at 23.10 EUR (25.87 USD).
The expected revenue of Neurogene is 462,500.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Neurogene is -86.35 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Neurogene is currently -4.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neurogene stock.
The price-to-sales ratio (P/S) of Neurogene is currently 866.42. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neurogene stock.
The Eulerpool Quality Score for Neurogene is 2/10.
The ISIN of Neurogene is US64135M1053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Neurogene is NGNE. The ticker symbol is used to trade Neurogene shares on the stock exchange.
Neurogene stock
Neurogene Peer Group
All fundamentals and in-depth analysis of Neurogene
Our stock analysis for Neurogene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neurogene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.